Who are metformin+empagliflozin+insulin glargine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-empagliflozin-insulin-glargine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

metformin+empagliflozin+insulin glargine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

metformin+empagliflozin+insulin glargine (metformin+empagliflozin+insulin glargine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor, insulin analog, biguanide. Area: Diabetes.

phase 3 SGLT2 inhibitor, insulin analog, biguanide SGLT2, insulin receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

metformin+empagliflozin+insulin glargine (metformin+empagliflozin+insulin glargine) — Xiangya Hospital of Central South University. Metformin works by decreasing glucose production in the liver and increasing insulin sensitivity, while empagliflozin inhibits SGLT2 to reduce glucose reabsorption in the kidneys, and insulin glargine is a long-acting insulin analog that helps lower blood sugar levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
metformin+empagliflozin+insulin glargine TARGET	metformin+empagliflozin+insulin glargine	Xiangya Hospital of Central South University	phase 3	SGLT2 inhibitor, insulin analog, biguanide	SGLT2, insulin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor, insulin analog, biguanide class)

Xiangya Hospital of Central South University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metformin+empagliflozin+insulin glargine — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-empagliflozin-insulin-glargine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab